| TOVX Stock | | | USD 1.34 0.06 4.69% |
This module uses fundamental data of Theriva Biologics to approximate the value of its Beneish M Score. Theriva Biologics M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out
Theriva Biologics Piotroski F Score and
Theriva Biologics Altman Z Score analysis.
For more information on how to buy Theriva Stock please use our
How to Invest in Theriva Biologics guide.
At this time, Theriva Biologics'
Short and Long Term Debt is fairly stable compared to the past year.
Debt To Equity is likely to rise to 0.02 in 2024, despite the fact that
Net Debt is likely to grow to (20
M). At this time, Theriva Biologics'
Book Value Per Share is fairly stable compared to the past year.
Average Payables is likely to rise to about 761.9
K in 2024, whereas
Price To Sales Ratio is likely to drop 241.35 in 2024.
At this time, it appears that Theriva Biologics is an unlikely manipulator. The earnings manipulation may begin if Theriva Biologics' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Theriva Biologics executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Theriva Biologics' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-4.22
Beneish M Score - Unlikely Manipulator
| Elasticity of Receivables | |
| Financial Leverage Condition | |
Theriva Biologics Beneish M-Score Indicator Trends
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Theriva Biologics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Theriva Biologics Beneish M-Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical
financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Theriva Biologics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Theriva Biologics in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Theriva Biologics' degree of accounting gimmicks and manipulations.
Click cells to compare fundamentals
About Theriva Biologics Beneish M Score
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled
The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed
financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
About Theriva Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Theriva Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Theriva Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at
the intrinsic value of Theriva Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing
financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our
fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Theriva Stock Analysis
When running Theriva Biologics' price analysis, check to
measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to
predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.